Published in Med Phys on April 01, 2001
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry (1986) 1.84
Hydrocarbon exposure and Parkinson's disease. Neurology (2000) 1.70
Evaluation of cerebral perfusion reserve in patients with carotid-artery occlusion. Lancet (1984) 1.70
Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry (2005) 1.69
Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain (1996) 1.64
Mesiobasal versus lateral temporal lobe epilepsy: metabolic differences in the temporal lobe shown by interictal 18F-FDG positron emission tomography. Neurology (1993) 1.59
Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology (1997) 1.55
Activation of the human brain by monetary reward. Neuroreport (1997) 1.52
Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol (1997) 1.49
Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med (1999) 1.48
Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol (1997) 1.34
Changes in brain activation associated with reward processing in smokers and nonsmokers. A positron emission tomography study. Exp Brain Res (2001) 1.32
Pure amnesia after unilateral left polar thalamic infarct: topographic and sequential neuropsychological and metabolic (PET) correlations. J Neurol Neurosurg Psychiatry (1994) 1.30
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology (1997) 1.30
How does the human brain deal with a spinal cord injury? Eur J Neurosci (1998) 1.27
Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm (Vienna) (2008) 1.25
Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med (2001) 1.25
Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol (1989) 1.24
Correction for the presence of intravascular oxygen-15 in the steady-state technique for measuring regional oxygen extraction ratio in the brain: 2. Results in normal subjects and brain tumour and stroke patients. J Cereb Blood Flow Metab (1983) 1.22
The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain (1985) 1.20
Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res (2000) 1.19
Reward mechanisms in the brain and their role in dependence: evidence from neurophysiological and neuroimaging studies. Brain Res Brain Res Rev (2001) 1.16
Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. J Neurol Neurosurg Psychiatry (1984) 1.16
Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol (1992) 1.13
Cerebral haemodynamics in occlusive carotid-artery disease. Lancet (1985) 1.13
Dopa-responsive dystonia: [18F]dopa positron emission tomography. Ann Neurol (1991) 1.13
Sensory tricks in cervical dystonia: perceptual dysbalance of parietal cortex modulates frontal motor programming. Ann Neurol (2000) 1.11
Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology (1985) 1.10
Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology (2001) 1.09
Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging (2008) 1.08
Differential effect of spinal cord injury and functional impairment on human brain activation. J Neurotrauma (2002) 1.08
Dexamethasone treatment of brain tumor patients: effects on regional cerebral blood flow, blood volume, and oxygen utilization. Neurology (1985) 1.07
Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol (1995) 1.07
Bradykinesia in early Huntington's disease. Neurology (2000) 1.05
T2 relaxation time in patients with Parkinson's disease. Neurology (1993) 1.05
Changes in reward-induced brain activation in opiate addicts. Eur J Neurosci (2001) 1.04
Measurement of regional cerebral blood flow, blood volume and oxygen metabolism in patients with sickle cell disease using positron emission tomography. Stroke (1986) 1.03
Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain (1997) 1.03
Neural activity related to the processing of increasing monetary reward in smokers and nonsmokers. Eur J Neurosci (2003) 1.03
Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol (1986) 1.02
PET before and after surgery for tumor-induced parkinsonism. Neurology (1986) 1.02
Measurement of regional cerebral pH in human subjects using continuous inhalation of 11CO2 and positron emission tomography. J Cereb Blood Flow Metab (1984) 1.00
Noninvasive dopamine determination by reversed phase HPLC in the medium of free-floating roller tube cultures of rat fetal ventral mesencephalon: a tool to assess dopaminergic tissue prior to grafting. Brain Res Bull (1996) 1.00
[11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol (1998) 0.99
Dopamine D2 receptors in normal human brain: effect of age measured by positron emission tomography (PET) and [11C]-raclopride. Ann N Y Acad Sci (1993) 0.99
Intermanual transfer of proximal and distal motor engrams in humans. Exp Brain Res (1996) 0.99
5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride. Neuropsychopharmacology (1999) 0.99
Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain (2010) 0.98
Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. Arch Neurol (1993) 0.97
Reduced reward processing in the brains of Parkinsonian patients. Neuroreport (2000) 0.97
Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET. J Neurol Sci (1995) 0.97
[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology (1994) 0.97
Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord (1997) 0.97
Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol (1992) 0.96
Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology (2005) 0.95
Grey matter volumetric changes related to recovery from hand paresis after cortical sensorimotor stroke. Brain Struct Funct (2014) 0.94
[11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord (2009) 0.94
Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease. Parkinsonism Relat Disord (2008) 0.93
Cerebral representations of space and time. Neuroimage (2008) 0.92
Right parieto-premotor activation related to limb-independent antiphase movement. Cereb Cortex (2002) 0.91
The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology (2001) 0.91
In vivo evaluation of striatal dopamine reuptake sites using 11C-nomifensine and positron emission tomography. Acta Neurol Scand (1987) 0.90
Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type. Arch Neurol (1990) 0.90
Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease. Eur J Neurol (2008) 0.89
Influence of spinal cord injury on cerebral sensorimotor systems: a PET study. J Neurol Neurosurg Psychiatry (1997) 0.89
Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res (2000) 0.89
Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet (1989) 0.88
A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography. J Cereb Blood Flow Metab (1990) 0.88
Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun (1994) 0.88
Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging (2005) 0.88
Regional cerebral oxygen utilization, blood flow, and blood volume in benign intracranial hypertension studied by positron emission tomography. Neurology (1985) 0.86
Crossed cerebellar diaschisis and brain tumor biochemistry studied with positron emission tomography, [18F]fluorodeoxyglucose and [11C]methionine. J Neurol Sci (1998) 0.86
Cerebral activation related to skills practice in a double serial reaction time task: striatal involvement in random-order sequence learning. Brain Res Cogn Brain Res (2004) 0.86
Increased cerebral iron uptake in Wilson's disease: a 52Fe-citrate PET study. J Nucl Med (2000) 0.86
Familial carnitine deficiency. A fatal case and subclinical state in a sister. J Neurol Sci (1979) 0.85
Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med (1998) 0.84
Cerebral activation related to implicit sequence learning in a Double Serial Reaction Time task. Brain Res (2006) 0.84
Leg muscle activation during gait in Parkinson's disease: influence of body unloading. Electroencephalogr Clin Neurophysiol (1997) 0.84
Epilepsia partialis continua studied by PET. Epilepsy Res (1991) 0.84
Blood flow and oxygen utilisation in the contralateral cerebral cortex of patients with untreated intracranial tumours as studied by positron emission tomography, with observations on the effect of decompressive surgery. J Neurol Neurosurg Psychiatry (1985) 0.84
Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease. J Neurol (2005) 0.84
Increased activation in cingulate cortex in conversion disorder: what does it mean? J Neurol Sci (2009) 0.84
Positron emission tomography of the brain: new possibilities for the investigation of human cerebral pathophysiology. Prog Neurobiol (1984) 0.83
Electrophysiological study, biodistribution in mice, and preliminary PET evaluation in a rhesus monkey of 1-amino-3-[18F]fluoromethyl-5-methyl-adamantane (18F-MEM): a potential radioligand for mapping the NMDA-receptor complex. Nucl Med Biol (1998) 0.83
Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res (1998) 0.83
Quantitative measurement of blood-brain barrier permeability using rubidium-82 and positron emission tomography. J Cereb Blood Flow Metab (1984) 0.82
Thalamic glucose metabolism in temporal lobe epilepsy measured with 18F-FDG positron emission tomography (PET). Epilepsy Res (1997) 0.82
Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A. Nucl Med Biol (1996) 0.82
Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol (1996) 0.82
Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. Magn Reson Imaging (1999) 0.81
Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography. Ann Neurol (2000) 0.81
Impaired somatosensory discrimination of shape in Parkinson's disease: association with caudate nucleus dopaminergic function. Hum Brain Mapp (1999) 0.81
Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. J Neurochem (1994) 0.81
What is the role of the corpus callosum in intermanual transfer of motor skills? A study of three cases with callosal pathology. Exp Brain Res (1997) 0.81
Evaluation of cerebral perfusion reserve in patients with carotid-artery occlusion. Lancet (1984) 0.81
Positron emission tomography in patients with primary CNS lymphomas. J Neurooncol (1999) 0.81
Whole body [O-15]water pharmacokinetics measured in blood. Physiol Meas (2003) 0.81